-
Product Insights
Likelihood of Approval Analysis for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Overview How likely is it that the drugs in Coronary Artery Disease (CAD) (Ischemic Heart Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Coronary Artery Disease (CAD) (Ischemic Heart Disease)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ninerafaxstat in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ninerafaxstat in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ninerafaxstat in Coronary Artery Disease (CAD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adrabetadex in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrabetadex in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrabetadex in Coronary Artery Disease (CAD) (Ischemic...
-
Product Insights
Heart Valve Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Heart Valve Disease - Drugs In Development, 2023’, provides an overview of the Heart Valve Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Heart Valve Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Congenital Heart Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Congenital Heart Disease - Drugs In Development, 2023’, provides an overview of the Congenital Heart Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Likelihood of Approval Analysis for Congestive Heart Failure (Heart Failure)
Overview How likely is it that the drugs in Congestive Heart Failure (Heart Failure) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Congestive Heart Failure (Heart Failure) Overview Heart failure (HF),...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golocdacimab in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golocdacimab in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golocdacimab in Coronary Artery Disease (CAD) (Ischemic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selnoflast in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selnoflast in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selnoflast in Coronary Artery Disease (CAD) (Ischemic...
-
Sector Analysis
NewComputed Tomography (CT) Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Computed Tomography (CT) Systems Market Report Overview The computed tomography (CT) systems market size was $5.63 billion in 2023. The market is expected to grow at a CAGR of more than 3% during 2023-2033. Computed tomography (CT) is a powerful, non-destructive evaluation technique used for producing 2D and 3D cross-sectional images of an object from a flat X-ray image. This technique is used in patients with a high risk of colon cancer. CT is also performed for full-motion heart scans...